Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Peptides

Mar 24, 2011 7:20am

NEW YORK, March 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Colorectal Cancer, Leukemia and Peptides

http://www.reportlinker.com/p0284609/Triple-Analysis-Colorectal-Cancer-Leukemia-and-Peptides.html

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Leukemia

The leukemia report part comprises defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. This report part extensively analyses 136 identified targets of leukemia drugs, organized into 115 drug target strategies, and assesses them in leukemia.

This part is based on the following publication:

Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Part III: Peptides

The peptide report part comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. This report part extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.

This part is based on the following publication:

Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451

7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699

8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039

10 Disclaimer 1040

11 Drug Index 1041

12 Company Index 1050

Figures: Includes 6 Figures

Tables: Includes 242 Tables

Total Number of Pages: 1,056

Part II: Leukemia

5 Introduction 22

6 Single Drug Target Benchmarking from the Leukemia Pipeline (136 Drug Targets) 25-265

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline? (115 Drug Target Strategies and 175 Drugs) 266-293

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound (7 Different Compound Strategies) 294-324

9 Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator (126 Investigators) 325-513

11 Drug Index 515

12 Company Index519

Figures: Includes 7 Figures

Tables: Includes 156 Tables

Total Number of Pages: 522

Part III: Peptides

5.1 The Scope of this Report 24

5.2 The Competitive Advantage and Disadvantage of Peptide Drugs 26

6 Consider the Therapeutic Peptide Target for the Highest Therapeutic Outcome and Return on Investment (125 Drug Targets) 29-219

7 Emerging New Products to Established Ones: Drug Target Strategies of Peptides by their Highest Stage of Development in Oncology (103 Drug Target Strategies and 145 Peptide Drugs) 220-246

8 Selecting Cancer Indications for Peptide Drugs (52 Cancer Indications) 247-300

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (103 Investigators) 301-586

10 Disclaimer 588

11 Drug Index 589

12 Company Index 593

Figures: Includes 4 Figures

Tables: Includes 192 Tables

Total Number of Pages: 596

To order this report:

: Triple Analysis: Colorectal Cancer, Leukemia and Peptides

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!